Abbott organic outlook cut, says Wolfe Research

Wolfe Research says the headline looks like Abbott (ABT) affirmed a prior “real” revenue growth outlook of 6.5%-7.5%. However, this was the prior “organic” range and now it’s the “comparable” range, so the firm’s conclusion is that “apples-to-apples” the 2026 organic revenue growth outlook range was reduced about 1%, the analyst tells investors. The firm has a Peer Perform rating on Abbott shares, which are down $4.66, or nearly 5%, to $96.90 in pre-market trading as the company begins its earnings conference call.